OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
AASK50

Aashka Hospitals Ltd

Healthcare Facilities & ServicesVerified

Aashka Hospitals Ltd has a basic and diluted share count of 23.4 million shares, indicating no immediate dilution pressure from share issuance. However, the liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The company's profitability and return metrics are not available in the current dataset, making it difficult to compare its performance against industry benchmarks or preferred metrics. Without these figures, an assessment of its operational efficiency and financial health cannot be made. Aashka Hospitals Ltd's revenue concentration and geographic exposure are not disclosed in the available data. This lack of information limits the ability to evaluate the company's risk profile from a geographic or segmental perspective. The growth trajectory of the company is also unclear, as there are no numeric deltas or revenue history provided in the dataset. This absence of data hinders the ability to forecast future performance or assess the company's market position. The risk assessment indicates a low level of dilution risk, but the liquidity risk remains unknown. The absence of balance-sheet inputs and no going-concern language in the source documents prevents a more detailed evaluation of the company's financial stability. There are no recent events, such as filings or transcripts, provided in the dataset to inform the company's current status or strategic direction.

30-day price · AASK+13.50 (+22.5%)
Low$59.00High$83.99Close$73.50As of15 May, 00:00 UTC
Profile
CompanyAashka Hospitals Ltd
TickerAASK.BO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. (unavailable from LLM output)

Classification. (unavailable from LLM output)

Aashka Hospitals Ltd has a basic and diluted share count of 23.4 million shares, indicating no immediate dilution pressure from share issuance. However, the liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The company's profitability and return metrics are not available in the current dataset, making it difficult to compare its performance against industry benchmarks or preferred metrics. Without these figures, an assessment of its operational efficiency and financial health cannot be made. Aashka Hospitals Ltd's revenue concentration and geographic exposure are not disclosed in the available data. This lack of information limits the ability to evaluate the company's risk profile from a geographic or segmental perspective. The growth trajectory of the company is also unclear, as there are no numeric deltas or revenue history provided in the dataset. This absence of data hinders the ability to forecast future performance or assess the company's market position. The risk assessment indicates a low level of dilution risk, but the liquidity risk remains unknown. The absence of balance-sheet inputs and no going-concern language in the source documents prevents a more detailed evaluation of the company's financial stability. There are no recent events, such as filings or transcripts, provided in the dataset to inform the company's current status or strategic direction.
Key takeaways
  • Aashka Hospitals Ltd has a basic and diluted share count of 23.4 million shares, indicating no immediate dilution pressure.
  • The company's liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.
  • Profitability and return metrics are not available, making it difficult to compare the company's performance against industry benchmarks.
  • Revenue concentration and geographic exposure are not disclosed, limiting the ability to evaluate the company's risk profile.
  • Growth trajectory and revenue history are not provided, hindering the ability to forecast future performance.
  • No recent events are available to inform the company's current status or strategic direction.
  • --
  • **RATIONALES**:
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$406.9M$73.1M$41.1M-$12.6M
FY-3$397.3M$53.7M$23.7M$34.0M
FY-2$189.4M-$26.9M-$25.7M$2.9M
FY-1$228.7M$15.4M$23.6M$46.0M
FY0$226.5M$22.6M$32.7M$48.3M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$650.8M$292.5M
FY-3$1.29B$965.6M
FY-2$1.28B$939.2M
FY-1$1.21B$962.7M
FY0$1.16B$995.4M
PeriodOCFCapExFCFSBC
FY-4$145.0M-$79.8M-$12.6M
FY-3-$626.3M-$18.7M$34.0M
FY-2$40.9M-$702.0k$2.9M
FY-1$71.8M-$6.7M$46.0M
FY0$91.9M-$13.8M$48.3M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricAASKActivity
Op margin7.7% medp25 -2.4% · p75 15.5%
Net margin5.9% medp25 -3.8% · p75 12.8%
Gross margin45.5% medp25 31.1% · p75 62.9%
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-7.0% medp25 -14.9% · p75 -3.2%
Debt / equity25.0% medp25 3.8% · p75 63.3%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-02 01:49 UTC#6c285253
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 05:53 UTCJob: 6fcc6257